IP Library Granted Patent US 8,404,735
Granted Patent B2
US 8,404,735 · App. 13/442,529 · Granted Mar 26, 2013

Parasiticidal formulation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,404,735
App. No.
13/442,529
Granted
Mar 26, 2013
Kind
B2
Abstract

The present invention provides a parasiticidal formulation comprising: Fipronil, or a veterinarily acceptable derivative thereof; at least one C 1 -C 6 alcohol co-solvent, wherein the total amount of C 1 -C 6 alcohol is up to 8% by weight of the formulation; at least one organic solvent which is not the C 1 -C 6 alcohol co-solvent; and at least one crystallization inhibitor, wherein the total amount of crystallization inhibitor is from 2 to 20% by weight of the formulation. The formulations of the invention have higher flash points than known parasiticidal formulations comprising Fipronil and therefore provide safer formulations for use in the home, storage, manufacture and distribution.

Claims (44)

1. A parasiticidal formulation comprising:

from about 8% to about 12% by weight Fipronil, or a veterinarily acceptable derivative thereof;

a C1-C6 alcohol, wherein the total amount of the C1-C6 alcohol is about 5% by weight of the formulation; and

at least one organic solvent which is not the C1-C6 alcohol.

2. The formulation of claim 1 , further comprising at least one crystallization inhibitor, wherein the total amount of the crystallization inhibitor is from 2 to 20% by weight of the formulation.

3. The formulation of claim 1 , wherein the Fipronil or a veterinarily acceptable derivative thereof, is Fipronil.

4. The formulation of claim 1 , which further comprises S-Methoprene.

5. The formulation of claim 4 , wherein the amount of S-Methoprene is from about 5% to about 25% by weight of the formulation.

6. The formulation of claim 2 , wherein the at least one crystallization inhibitor is polyethylene glycol, polyethylene glycol hydrogenated castor oil, or combinations thereof.

7. The formulation of claim 6 , wherein the at least one crystallization inhibitor is a combination of polyethylene glycol and polyethylene glycol hydrogenated castor oil.

8. The formulation of claim 7 , wherein the amount of polyethylene glycol is about 5% by weight of the formulation and the amount of polyethylene glycol hydrogenated castor oil is about 5% by weight of the formulation.

9. The formulation of claim 1 , wherein the at least one organic solvent which is not the C1-C6 alcohol is diethylene glycol monoethyl ether, ethylene glycol monoethyl ether, dipropylene glycol n-butyl ether, dipropylene glycol monomethyl ether, or combinations thereof.

10. The formulation of claim 9 , wherein the at least one organic solvent which is not the C1-C6 alcohol is diethylene glycol monoethyl ether.

11. A method for controlling parasites on mammals in need thereof, said method comprising treating the mammal by application to the skin of parasiticidally effective dose of a formulation of claim 1 .

12. The method of claim 11 , wherein the mammal is treated by local point application to the skin of a spot-on formulation of claim 1 .

13. The method of claim 11 , wherein the parasites are one or more ectoparasites.

14. A parasiticidal formulation consisting of:

about 9.7 wt % Fipronil;

about 5.0 wt % ethanol;

about 0.02 wt % butylated hydroxylanisole;

about 0.01 wt % butylated hydroxyltoluene;

about 5.0 wt % polyethylene glycol 1000;

about 5.0 wt % polyethylene glycol 60 hydrogenated castor oil;

balance diethylene glycol monoethyl ether.

15. A parasiticidal formulation consisting of:

about 9.8 wt % Fipronil;

about 11.8 wt % S-Methoprene;

about 5.0 wt % ethanol;

about 0.02 wt % butylated hydroxylanisole;

about 0.01 wt % butylated hydroxyltoluene;

about 5.0 wt % polyethylene glycol 1000;

about 5.0 wt % polyethylene glycol 60 hydrogenated castor oil;

balance diethylene glycol monoethyl ether.

16. A parasiticidal formulation consisting of:

about 9.8 wt % Fipronil;

about 8.8 wt % S-Methoprene;

about 5.0 wt % ethanol;

about 0.02 wt % butylated hydroxylanisole;

about 0.01 wt % butylated hydroxyltoluene;

about 5.0 wt % polyethylene glycol 1000;

about 5.0 wt % polyethylene glycol 60 hydrogenated castor oil;

balance diethylene glycol monoethyl ether.

17. The method of claim 11 , wherein the mammals are cats or dogs.

18. The method of claim 13 , wherein the one or more ectoparasites are fleas and ticks.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Oct 29, 2024
From: JEFFERIES FINANCE LLC
To: PETIQ HOLDINGS, LLC; PETIQ, LLC; SERGEANT’S PET CARE PRODUCTS, LLC; COMMUNITY VETERINARY CLINICS, LLC; FIDOPHARM, INC.; TRURX LLC; VELCERA, LLC
Reel/Frame 069052/0290 →
RELEASE OF SECURITY INTEREST Recorded Oct 29, 2024
From: KEYBANK NATIONAL ASSOCIATION
To: PETIQ HOLDINGS, LLC; PETIQ, LLC; SERGEANT’S PET CARE PRODUCTS, LLC; COMMUNITY VETERINARY CLINICS, LLC; FIDOPHARM, INC.; TRURX LLC; VELCERA, LLC
Reel/Frame 069269/0614 →
FIRST LIEN PATENT SECURITY AGREEMENT (TL) Recorded Oct 28, 2024
From: PETIQ, INC.; PETIQ, LLC; TRURX LLC; VELCERA, LLC; FIDOPHARM, INC.; SERGEANT’S PET CARE PRODUCTS, LLC
To: ARES CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 069272/0659 →
ABL PATENT SECURITY AGREEMENT Recorded Oct 28, 2024
From: PETIQ, INC.; PETIQ, LLC; TRURX LLC; VELCERA, LLC; FIDOPHARM, INC.; SERGEANT’S PET CARE PRODUCTS, LLC
To: KEYBANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 069272/0670 →
SECURITY INTEREST Recorded Apr 14, 2021
From: PETIQ HOLDINGS, LLC; PETIQ, LLC; SERGEANT'S PET CARE PRODUCTS, LLC; COMMUNITY VETERINARY CLINICS, LLC; FIDOPHARM, INC.; TRURX LLC; VELCERA, LLC
To: JEFFERIES FINANCE LLC
Reel/Frame 055915/0408 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 10, 2013
From: CIPLA LIMITED
To: OMNIPHARM LIMITED
Reel/Frame 030769/0312 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2013
From: DONNELLY, MARTIN BENEDICT GEORGE
To: OMNIPHARM LIMITED
Reel/Frame 029650/0043 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2013
From: OMNIPHARM LIMITED
To: FIDOPHARM, INC.
Reel/Frame 029650/0090 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2013
From: QEDETAL LIMITED
To: FIDOPHARM, INC.
Reel/Frame 029650/0109 →